DGMT CTP In Vivo MN kits

The contract involves the procurement of DGMT CTP In Vivo MN kits and Comet assay supplies, specifically referenced under the names Manju C24020 and Carol. It is associated with the Food and Drug Administration (FDA), targeting materials classified under NAICS code 325414, which pertains to pharmaceutical preparation manufacturing. This procurement is currently in the forecast stage as of March 11, 2026, indicating anticipated upcoming acquisition needs for these specialized kits and supplies used in genotoxicity testing. Key contact information includes the NCTR Acquisitions Liaison, responsible for program-related inquiries, with contracting officer details yet to be determined. The contract's place of performance and specific location details are not provided. This forecast signals the FDA’s intent to acquire these scientific supplies, which support in vivo micronucleus (MN) assays and comet assays, essential tools in toxicology and genetic damage assessment within pharmaceutical and biomedical research domains.